Nanooncology: The breast cancer story

University of Toronto Medical Journal

Volumn 88, Issue 3, 2011, Pages 190-194

  Rastogi, Anjali ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957664900     PISSN: 08332207     EISSN: 19135440     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2010. Toronto, Canada, 2010.
2. Mahesh M. AAPM/RSNA physics tutorial for residents: digital mammography: an overview. Radiographics. 2004;24(6):1747-1760.
3. Chen Z. Small molecule delivery by nanoparticles for anticancer therapy. Trends in molecular medicine. 2010;16(12):594-602.
4. Fenniri H. The Canadian Regenerative Medicine and Nanomedicine Enterprise (CARMENE). Int J Nanomedicine. 2006;1(3):225-227.
5. Terminology for nanomaterials [Internet]. Publicly available specification 136. London: British Standards Institute; c2007 [cited 2010 Dec 20]. Available from: www.nanointeract.net/x/file/PAS%20136.pdf
6. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-171.
7. Kim BYS, Rutka JT, Chan WCW. Nanomedicine. NEJM. 2010;363:2434-2443.
8. Xia Y, Xiong YJ, Lim B, Skrabalak SE. Shape-controlled synthesis of metal nanocrystals: simple chemistry meets complex physics? Angew Chem Int Ed Engl. 2009;48:60-103.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60.
10. Yezhelyev MV, Gao X, Xing Y, Al Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006;7:657-67.
11. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4:95-99.
12. Rosenthal E, Poizot-Martin I, Saint-Marc T, Spano JP, Cacoub P, DNX Study Group. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDSrelated Kaposi sarcoma. Am J Clin Oncol. 2002;25:57-59.
13. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003;21:3249-3259.
14. Markman M. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother. 2006;7:1469-1474.
15. Rivera E. Current status of liposomal anthracycline therapy in metastatic breast cancer. Clin Breast Cancer. 2003;4(2):S76-83.
16. Swenson S, Tomalia DA. Dendrimers in biomedical applications: reflections on the field. Adv Drug Deliv Rev. 2005;57:2106-2129.
17. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol. 2005;9:674-679.
18. Pramanik M, Hyun Song K, Swierczewska M, Green D, Sitharaman B, Wang LV. In vivo carbon nanotube-enhanced non-invasive photoacoustic mapping of the sentinel lymph node. Phys Med Biol. 2009;54(11):3291-3301.
19. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science. 2003;301:1884-1886.
20. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003;49(3):403-408.
21. Zhou J, Leuschner C, Kumar C, Hormes JF, Soboyejo WO. Subcellular accumulation of magnetic nanoparticles in breast tumours and metastases. Biomaterials. 2006;27(9):2001-2008.
22. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. Nanoshell-mediated near-infrared thermal therapy of tumours under magnetic resonance guidance. Proc Natl Acad Sci USA. 2003;100:13549-13554.
23. Li J, Wu D, Miao Z, Zhang Y. Preparation of quantum dot bioconjugates and their applications in bio-imaging. Curr Pharm Biotechnol. 2010;11(6):662-671.
24. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371(9606):29-40.
25. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003;98(12):2547.
26. Haq AI, Zabkiewicz C, Grange P, Arya M. Impact of nanotechnology in breast cancer (Report). Expert review of anticancer therapy. 2009;4:1021-1028.
27. Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomed Microdevices. 2009;11(1):49-63.
28. Gao X, Cui Y, Levenson RM. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969-976.
29. Yezhelyev MV, Al Hajj A, Morris C, Marcus AI, Liu T, Lewis M, Cohen C, Zrazhevskiy P, Simons JW, Rogatko A, Nie S, Gao X, O'Regan RM. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv. Materials. 2007;19:3146-3151.
30. Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, Chung LW, Petros JA, O'Regan RM, Yezhelyev MV, Simons JW, Wang MD, Nie S. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc. 2007;2(5):1152-1165.
31. Xiao Y, Telford WG, Ball JC, Locascio LE, Barker PE. Semiconductor nanocrystal conjugates, FISH and pH. Nat Methods. 2005;2(10):723.
32. Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, Hanby A, Brown J. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010;375(9714):563-71.
33. Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology. 2008;246(1):116-24.
34. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA. 2002;99:126117-126121.
35. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. Targeted nanoparticles for detecting and treating cancer. Drug Dev Res. 2006;67:70-93.
36. Pan D, Lanza GM, Wickline SA, Caruthers SD. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol. 2009;70(2):274-285.
37. Tada H, Higuchi H, Wanatabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 2007;67(3):1138-1144.
38. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect. 2006;114:165-172.
39. Mabry H, Giuliano AE. Sentinel node mapping for breast cancer: progress to date and prospects for the future. Surg Oncol Clin N Am. 2007;16(1):55-70.
40. Latosinsky S, Dabbs K, Moffat F, Evidence-Based Reviews in Surgery Group. Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Can J Surg. 2008;51(6):483-485.
41. Song KH, Kim C, Maslov K, Wang LV. Noninvasive in vivo spectroscopic nanorod-contrast photoacoustic mapping of sentinel lymph nodes. Eur J Radiol. 2009;70(2):227-231.
42. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
43. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16(13):1656-1672.
44. Malem Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592-599.
45. Batist G, Ramakrishman G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Reduced cardiotoxicity and preserved antitumour efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444-1454.
46. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
47. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008;8(9):2851-2857.
48. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremaphor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-1598.
49. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from Taxol. J Clin Oncol.1990;8:1263-1268.
50. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
51. Gao Y, Chen L, Zhang Z, Chen Y, Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials. 2011;32:1738-1747.
52. Jain KK. Nanobiotechnology: Technologies, Markets and Companies. Basel, Switzerland: Jain PharmaBiotech Publications; 2010.